Article 1 to 7 out of 7 concerning Protox Therapeutics Inc.
Protox doses first patient in Phase 2 BPH clinical trial(05/19/2008) Protox Therapeutics Inc. announced the enrolment and successful dosing of the first patient in a Phase 2 clinical trial evaluating PRX302 to treat benign prostatic hyperplasia (BPH), or enlarged prostate."This milestone sets the stage for a very ...
Protox announces positive long-term data from BPH study(04/21/2008) Protox Therapeutics Inc. announced positive results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common and bothersome urological condition among the aging male population. The results indicate that ...
Protox announces positive final results from BPH study(01/07/2008) Protox(TM) Therapeutics Inc. announced positive final results from its Phase 1 study evaluating PRX302 in patients with benign prostatic hyperplasia (BPH), a common condition among the aging male population. The trial results indicate that PRX302 is ...
Protox acquires research program from Medicenna(08/23/2007) Protox Therapeutics Inc. announced that it has entered into an asset purchase agreement with Medicenna Ventures Inc. for the acquisition of Medicenna's HUMxin(TM) Program, a research program to develop fully humanized fusion proteins based upon the ...
Protox files foundation patent for PORxin(TM) technology(12/15/2005) Protox Therapeutics Inc. announced that it has filed a provisional patent application with the United States Patent and Trademark Office entitled "Modified Pore-Forming Toxins and Use Thereof". This is a foundational patent application, intended to ...
Protox signs exclusive Lung Cancer licence agreement and initiates Lung Cancer study(08/11/2005) Protox Therapeutics Inc. announced that it has signed an exclusive licence agreement with the National Research Council Institute for Biological Sciences (NRC-IBS) and the University of Victoria (UVic) Innovation and Development Corporation (IDC). ...
Protox receives funding from NRC to develop lung cancer drug(06/09/2005) Protox Therapeutics Inc. announced that it has received a financial contribution of up to $340,000 from the National Research Council ('NRC') Industrial Research Assistance Program ('IRAP'). The NRC has committed this money to the Company to support ...
Top
